Welcome to DiscoveRx Assay News, a regular update about our products and services. In each issue we will discuss new products that are available, as well as applications of existing products and tips that may help you in your research. DiscoveRx assay solutions are based on our core proprietary Enzyme Fragment Complementation (EFC) technology, a proven, established screening technology in most major pharmaceutical companies. Through our HitHunter™, PathHunter™ and EFC technologies, DiscoveRx is able to offer assay solutions for every major class of drug target, including GPCRs, kinases, proteases, nuclear hormone receptors, transcription factors and secreted proteins.
Kinase Binding Assays for Unactive and Active Kinases:
- Only assay to identify novel inhibitors of unactive and active kinases
HitHunter™ Kinase Binding Assay Kits uniquely satisfy the need to identify inhibitors of both unactive and active kinases because they measure, in a competitive binding assay, the interaction of the inhibitor with the kinase. These assays are non-radioactive, homogeneous, and are designed for 384-well plates. Unlike functional kinase assays, they do not require the presence of either substrate or ATP.
PathHunter™ Mitotic Index Assay for Cancer Research:
- Only 384-well chemiluminescent assay for identifying anti-proliferative compounds
PathHunter Mitotic Index assays feature biosensor cell lines engineered with nuclear and cytoplasmic fragments of ß-galactosidase (ß-gal). At mitosis the nuclear envelope degrades and allows the ß-gal fragments to complement, forming an active enzyme that generates a chemiluminescent signal. The result is an easy, cost-effective HTS assay to identify compounds or biologicals that inhibit proliferation in mammalian cells.
ADP Hunter™ Plus Assay - New and Improved!
- Unique fluorescent assay to identify inhibitors of Kinases or ATPases
ADP Hunter Plus is an improved version of our original ADP Hunter assay and provides assay windows >25 fold, excellent Z' and increased sensitivity at ATP concentrations of up to 300 µM. The assay produces a positive fluorescent signal that is directly proportional to ADP accumulation, an end-product of kinase or ATPase activity. The fluorescent signal is red-shifted, minimizing interference from fluorescent compounds. Unlike the ATP depletion approach, ADP Hunter Plus gives robust performance even with high ATP or low activity enzymes.
Please visit us at:
Miptec 2006
Basel, Switzerland
May 8-11
IIR 4th annual Congress: GPCRs in Drug Discovery
Barcelona, Spain
May 22-25
World Pharmaceutical Congress
Philadelphia, PA
May 23-25
Society for Biomolecular Screening
Seattle, WA
Sept 17-21
DiscoveRx – Simple Solutions for Complex Biology
|
.jpg)